Immunotherapy efficacy in colorectal cancer is dependent on activation of a microbial-metabolite-immune circuit

Lukas F. Mager,Regula Burkhard,Noah C.A. Cooke,Kirsty Brown,Hena Ramay,Seungil Paik,John Stagg,Ryan A. Groves,Marco Gallo,Ian A. Lewis,Markus B. Geuking,Kathy D. McCoy
DOI: https://doi.org/10.1101/2020.02.26.965533
2020-02-27
Abstract:Summary Cancer is a leading cause of death globally. Checkpoint blockade therapies offer a promising treatment for many cancers, but have been ineffective for colorectal cancers. Previous studies have shown a dependency of immunotherapies on the microbiota. Consequently, we hypothesized that specific gut bacteria promote immunotherapy for colorectal cancer. We identify three commensal bacteria and a microbial metabolite, inosine, that enhance the efficacy of immune checkpoint blockade therapy in colorectal cancer. We show that inosine interacts with the adenosine A 2A receptor on T cells resulting in intestinal Th1 cell differentiation. Decreased gut barrier function induced by immunotherapy increased the translocation of bacterial metabolites and promoted cancer protective Th1 cell activation. This microbial-metabolite-immune circuit provides a mechanism for a new class of bacteria-enhanced checkpoint blockade therapies. The efficacy of this mechanism differs among colorectal cancer subtypes and highlights the strengths as well as potential limitations of this novel bacterial co-therapy for cancer.
What problem does this paper attempt to address?